Coronavirus: Medical Treatments

(asked on 15th June 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the role of covid-19 antivirals in reducing pressures on the NHS.


Answered by
Maggie Throup Portrait
Maggie Throup
This question was answered on 23rd June 2022

No specific assessment has been made. However, clinical trial results indicate that the dual oral antiviral nirmatrelvir/ritonavir resulted in a relative risk reduction of hospitalisation or death by 88% within five days of symptom onset, compared to placebo in non-hospitalised, high-risk adults with COVID-19. Further results show that the oral antiviral molnupiravir administered within five days of symptom onset to high-risk, non-hospitalised patients resulted in a relative risk reduction of 30% in the composite primary outcome of hospitalisation or death at day 29.

Reticulating Splines